[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
01 févr. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Group sales grow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding...
European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
16 janv. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC...
Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform
29 déc. 2023 16h30 HE
|
F. Hoffmann-La Roche Ltd
The transformative point of care solution will complement Roche’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease...
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
19 déc. 2023 09h40 HE
|
F. Hoffmann-La Roche Ltd
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study...
Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices
15 déc. 2023 01h15 HE
|
F. Hoffmann-La Roche Ltd
Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices The ranking acknowledges Roche’s commitment to sustainability as an integral part of its...
New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
11 déc. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of...
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A
09 déc. 2023 11h30 HE
|
F. Hoffmann-La Roche Ltd
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years...
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
08 déc. 2023 11h50 HE
|
F. Hoffmann-La Roche Ltd
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive...
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
08 déc. 2023 11h45 HE
|
F. Hoffmann-La Roche Ltd
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to...
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
05 déc. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in...